EP2381254B2 - Copolymeranalyse - Google Patents

Copolymeranalyse Download PDF

Info

Publication number
EP2381254B2
EP2381254B2 EP11172109.8A EP11172109A EP2381254B2 EP 2381254 B2 EP2381254 B2 EP 2381254B2 EP 11172109 A EP11172109 A EP 11172109A EP 2381254 B2 EP2381254 B2 EP 2381254B2
Authority
EP
European Patent Office
Prior art keywords
ifn
glatiramer acetate
cell
induced
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11172109.8A
Other languages
English (en)
French (fr)
Other versions
EP2381254A1 (de
EP2381254B1 (de
Inventor
Josephine S. D'alessandro
Takashi Kei Kishimoto
Aileen Healy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712646&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2381254(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of EP2381254A1 publication Critical patent/EP2381254A1/de
Application granted granted Critical
Publication of EP2381254B1 publication Critical patent/EP2381254B1/de
Publication of EP2381254B2 publication Critical patent/EP2381254B2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Definitions

  • the presently disclosed subject matter generally relates to methods of characterizing complex peptide or polypeptide mixtures. More particularly, the presently disclosed subject matter relates to cell-based methods for evaluating one or more properties of an amino acid copolymer.
  • Copolymer-1 is a complex mixture of polypeptides prepared from the polymerization of the amino acids glutamic acid, lysine, alanine and tyrosine. Copolymer-1 also is known as glatiramer acetate and has the following structural formula: (Glu, Ala, Lys , Tyr)x XCH 3 COOH (C 5 H 9 NO 4 •C 3 H 7 NO 2 •C 6 H 14 N 2 O 2 •C 9 H 11 NO 3 )x •XC 2 H 4 O 2
  • Glatiramer acetate is the active ingredient of COPAXONE® (Teva Pharmaceutical Industries Ltd., Israel), which comprises the acetate salts of synthetic polypeptides containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, with a reported average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively.
  • Glatiramer acetate is used in the treatment of the relapsing-remitting form of multiple sclerosis (RRMS).
  • WO 03/048735 A2 discloses a process for measuring the relative potency of a test batch of glatiramer acetate.
  • the present invention provides methods and compositions for evaluating one or more properties of a candidate agent, namely the amino acid copolymer glatiramer acetate as defined in claims 1, 2, 9, and 11.
  • a candidate agent namely the amino acid copolymer glatiramer acetate as defined in claims 1, 2, 9, and 11.
  • the invention provides a variety of embodiments for evaluating an amino acid copolymer preparation for physiological, pharmacodynamic, pharmacokinetic, or pharmaceutical properties including but not limited to potency, specificity, stability, biological activity, e.g., for suitability as a pharmaceutical preparation, e.g., for the treatment of autoimmune and/or inflammatory disease, disorders or dysfunctions.
  • One or more properties of the amino acid copolymer preparation can be evaluated by comparing the results from the assay (e.g., a qualitative or quantitative test value corresponding to the induction, production, secretion, presence or level of a regulated protein) to a reference value, e.g., a value predetermined to correlate to a particular level of potency, specificity, stability, and/or biological activity of copolymer, e.g., a value predetermined to correlate with a level of potency, specificity, stability, and/or biological activity of the copolymer suitable for a pharmaceutical preparation useful to treat a disease, disorder, or dysfunction described herein.
  • a reference value e.g., a value predetermined to correlate to a particular level of potency, specificity, stability, and/or biological activity of copolymer, e.g., a value predetermined to correlate with a level of potency, specificity, stability, and/or biological activity of the copolymer suitable for a pharmaceutical preparation useful to treat
  • the reference value is a cytokine induction profile, equivalence range or pharmaceutical specification for potency, specificity, stability, and/or biological activity for a marketed pharmaceutical preparation of glatiramer acetate.
  • the reference value is a value determined by direct measurement of a property of a reference compound, e.g., a reference glatiramer acetate preparation.
  • the test value is considered comparable to the reference value if it is within 25%, 20%, 15%, 10%, 5%, 2%, 1% or less of the reference value.
  • the cell used in the assay is a leukocyte, namely a myeloid cell, e.g., a myeloid cell line or primary cell, e.g., blood mononuclear cell (e.g., T cells, natural killer cells, monocytes, macrophages, etc.), blood polymorphonuclear cell (e.g., eosinophils, basophils, neutrophils, megakaryocytes, etc.), dendritic cell, and thymic cells.
  • the cell can be a tumorigenic myeloid cell line such as THP-1, U937, SiHa, or HL-60.
  • mammalian peripheral blood mononuclear cells as well as bone-marrow derived monocytes and monocytes may be used.
  • the protein regulated by the proinflammatory molecule IFN- ⁇ (whose induction, production, secretion, presence or level is detected in the assay) is a chemokine, e.g., an IFN-y regulated chemokine.
  • the chemokine is selected from the group consisting of: ⁇ -interferon-inducible protein 10 (IP-10), interferon-inducible T cell ⁇ -chemoattractant (I-TAC), monokine induced by ⁇ -interferon (MIG).
  • IP-10 ⁇ -interferon-inducible protein 10
  • I-TAC interferon-inducible T cell ⁇ -chemoattractant
  • MIG monokine induced by ⁇ -interferon
  • Other soluble proteins or cytokines induced by IFN- ⁇ include those shown in Table 1.
  • the induction, production, secretion, presence or level of a regulated protein can be detected directly, e.g., by an antibody-based method, such as an ELISA, or indirectly, e.g., by art-known techniques to detect transcripts for the protein or by use of a reporter gene assay.
  • exposure of the cell(s) to the amino acid copolymer and IFN- ⁇ results in a synergistic induction of one or more of the cytokine-regulated proteins.
  • exposure of myeloid cells to the amino acid copolymer glatiramer acetate and IFN ⁇ results in a synergistic induction of one or more IFN ⁇ -regulated chemokines or cytokines (e.g., of IP-10, I-TAC, MIG, and/or other CXCR3 ligands).
  • the induction of a regulated cytokine can be at least 5-fold; 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 75-fold, 100-fold, 150-fold, 200-fold, 300-fold or more over control values (e.g., over negative controls with no proinflammatory molecule and/or no copolymer).
  • the invention further provides a method of preparing a pharmaceutical composition of glatiramer acetate comprising preparing a batch of glatiramer acetate, evaluating the potency, specificity, biological activity and/or stability of the composition by a method described herein, and determining that the glatiramer acetate is acceptable for pharmaceutical use if at least a predetermined level of one or more proteins regulated by the cytokine is detected and/or if the regulated protein is induced to a level within 80%-125% (e.g., at least 80%, 85%, 90%, 95%, 98%, 100%, 110%, 115%, 120%, 125%) of a reference value.
  • 80%-125% e.g., at least 80%, 85%, 90%, 95%, 98%, 100%, 110%, 115%, 120%, 125%) of a reference value.
  • a method for preparing a pharmaceutical composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups and deprotecting TFA-protected lysines to generate glatiramer acetate; and isolating the glatiramer acetate, wherein the improvement comprises: measuring the expression of a IFN- ⁇ -induced protein in a myeloid cell or a primary myeloid cell line in the presence of IFN- ⁇ and a sample of the isolated glatiramar acetate and comparing the expression to reference value.
  • TFA trifluoroacetic acid
  • the improvement further comprises selecting the purified glatiramer acetate for use in the preparation of a pharmaceutical composition if the difference between the measured expression and the reference value is within a predetermined range; and the improvement further comprises: preparing a pharmaceutical composition comprising at least a portion of the selected purified glatiramer acetate.
  • Figure 1 illustrates the secretion of IP-10, I-TAC, and MIG over approximately 24 hours in various serum containing or serum-free media at a constant IFN ⁇ concentration (10 ng/ml).
  • the 10% FBS condition was tested at 50, 10, 2, and 0 ⁇ g/ml glatiramer acetate (GA).
  • the 2% FBS, 0% FBS, and X-VIVO15 conditions were analyzed at 50 and 0 ⁇ g/ml GA.
  • M represents the mannitol control carrier that was assayed at 100 ⁇ g/ml.
  • the numbers above the bars represent the fold increase over the control (0 ⁇ g/ml).
  • the present invention provides methods and compositions for evaluating one or more properties of glatiramer acetate which may be useful as a therapeutic preparation, e.g., for the treatment of an autoimmune, neurodegenerative, demyelinating or inflammatory disorder.
  • the assays described herein may be in any format known in the art, including cell culture assays, organ culture assays, or ex vivo assays.
  • a proinflammatory molecule is a molecule that stimulates activation of leukocytes, epithelial cells, or stromal cells resulting in the amplification or propagation of an inflammatory immune response.
  • a proinflammatory molecule can induce the production of activation markers (e.g., CD69, CD25, CD54, CD40 ligand, CD11b, CD62L, CD83, CD95) and/or secretion of other pro-inflammatory cytokines and/or chemokines from immune cells such as CD4 T cells, CD8 T cells, B cells, NK cells, monocytes, macrophages, dendritic cells, neutrophils, basophils, eosinophils, and mast cells.
  • activation markers e.g., CD69, CD25, CD54, CD40 ligand, CD11b, CD62L, CD83, CD95
  • other pro-inflammatory cytokines and/or chemokines from immune cells such as CD4 T cells, CD8 T cells, B cells, NK
  • the invention utilizes the proinflammatory cytokine IFN- ⁇ which is a small secreted protein that has the properties of a proinflammatory molecule as described herein.
  • A"chemokine” is a cytokine with chemotactic activity. Examples of chemokines include IL-8, RANTES, MIP-1a, MCP-1, IP-10, Mig, I-TAC, TARC, 1-309.
  • the various methods described herein can be used to evaluate one or more properties of a glatiramer acetate preparation, such as potency, specificity, stability, purity, and biological activity, by comparison of the test copolymer preparation to one or more predetermined reference value, such as a pharmaceutical specification value for potency, specificity, stability, and biological activity of glatiramer acetate.
  • a reference value can be determined by comparison to a known agent.
  • a preferred reference agent of the invention is an amino acid copolymer (e.g., a pharmaceutical preparation of glatiramer acetate) that is suitable for use as a pharmaceutical preparation, e.g., it has been shown to have therapeutic efficacy in one or more autoimmune, degenerative, demyelinating and/or inflammatory disorders or conditions.
  • therapeutic efficacy is intended that the agent is capable of preventing, treating or ameliorating symptoms associated with the disorder or condition.
  • the reference value is a predetermined pharmaceutical specification value for glatiramer acetate.
  • the reference compound is pharmaceutical preparation of glatiramer acetate.
  • the synergistic induction of cytokine-regulated proteins in various cell types when coadministered with exogenously supplied cytokine and copolymer-1 has been observed.
  • the term "synergistic" refers to two or more agents (e.g., glatiramer acetate and a cytokine) that are more effective in combination than the sum of the individual effects of each single agent alone. This synergistic induction of cytokine-regulated proteins can be used to screen a test copolymer preparation for properties, including biological activity, that are comparable to glatiramer acetate.
  • Glatiramer acetate is approved for reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. Multiple sclerosis has been classified as an autoimmune disease. Glatiramer acetate has also been disclosed for use in the treatment of other autoimmune diseases, inflammatory non-autoimmune diseases and to promote nerve regeneration and/or to prevent or inhibit secondary degeneration which may follow primary nervous system injury. Furthermore, glatiramer acetate has been disclosed as a treatment for immune mediated diseases as well as diseases associated with demyelination. The methods described herein can be used to evaluate the activity of a glatiramer acetate preparation for suitability as a pharmaceutical preparation for any of these disorders.
  • the methods and compositions of the present invention comprise assays useful for evaluating one or more properties of glatiramer acetate.
  • a test copolymer preparation is screened using an in vitro assay to evaluate the effect of the copolymer preparation on the production and/or secretion of one or more proteins regulated by IFN- ⁇ .
  • the level of IFN- ⁇ -regulated induction of the protein(s) in the presence of a test copolymer preparation is compared to the level of the proinflammatory cytokine-regulated induction of that protein(s) in the same cell type in the presence of a reference agent.
  • the level (i.e., qualitative or quantitative level) and nature (i.e., species of protein) of induction is referred to herein as the "cytokine induction profile.”
  • the cytokine induction profile can be used to assess one or more properties of glatiramer acetate, such as potency, stability, specificity, and biological activity.
  • a test preparation is said to be suitable as a pharmaceutical composition when the cytokine induction profile of the test preparation (e.g., the level of induction or the number of similar proteins that are induced, or both) is between about 80% and about 125%, including about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 105%, about 110%, about 115%, about 120%, up to about 125% of a reference value or profile for a copolymer pharmaceutical composition (e.g., a lot of COPAXONE®).
  • a reference value or profile for a copolymer pharmaceutical composition e.g., a lot of COPAXONE®
  • a test preparation is said to have substantially the same properties as a reference copolymer preparation (e.g., COPAXONE ®) when the cytokine induction profile of the test preparation (e.g., the level of induction or the number of similar proteins that are induced, or both) is between about 80% and about 125%, including about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 105%, about 110%, about 115%, 120%, up to about 125% of the reference copolymer preparation.
  • a reference copolymer preparation e.g., COPAXONE ®
  • the reference is glatiramer acetate with known therapeutic efficacy in one or more autoimmune or inflammatory disorders.
  • the reference agent is glatiramer acetate.
  • the reference value can be a value predetermined to correspond to a certain level of potency, purity, stability or other activity of glatiramer acetate.
  • One or more cells capable of producing or secreting a cytokine-regulated protein is contacted with glatiramer acetateor a reference agent at a concentration and time sufficient for the induction of the cytokine-regulated protein.
  • the assay may comprise two or more cell types, which may be primary cells, cell lines, or combinations thereof.
  • the concentration and time sufficient for the induction of the cytokine-regulated protein is that which results in the detectable production or secretion of the cytokine-regulated protein above the level of that protein in the absence of glatiramer acetateor reference agent (e.g., above baseline levels of the protein that is regulated by the cytokine).
  • the concentration of the glatiramer acetate may be present in the assay medium at a concentration of at least about 0.05 ⁇ g/mL, at least about 1 ⁇ g/mL, at least about 2 ⁇ g/mL, at least about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 25, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 125, about 150, about 175, about 200, about 225 about 250, about 275, about 300, about 375, about 400, about 425, about 450, about 475, at least about 500 ⁇ g/mL or greater, so long as the concentration does not reach that which is cytotoxic.
  • Glatiramer acetateor reference agent may be incubated (i.e., "contacted") with the cell capable of secreting or producing the cytokine-regulated protein for at least about 1 hour, at least about 1.5 hours, at least about 2 hours, at least about 3 hours, at least about 4 hours, about 5 hours, about 6 hours, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 40, about 45, about 48 or more hours.
  • an amount of the proinflammatory cytokine that regulates the expression of the protein described above may be added exogenously to the assay medium.
  • the cytokine can be added before, at the same time as, or after the addition of the test or reference copolymer preparation. In one embodiment, the cytokine is added at the same time as the test or reference copolymer preparation.
  • the cytokine can be present in the assay medium at a concentration of at least about 1 ng/ml, at least about 2 ng/ml, at least about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 25, about 30, about 40, at least about 50 ng/ml or greater, so long as the concentration does not reach that which is cytotoxic.
  • the cytokine can be heterologously expressed in the host cell of the assay.
  • the heterologous gene can be under the control of a constitutive or an inducible promoter.
  • the cytokine that regulates the production and secretion of the one or more proteins described herein is a proinflammatory cytokine.
  • Proinflammatory cytokines are typically associated with a Th1 T cell response.
  • the proinflammatory cytokine is selected from the group that includes, but is not limited to, TNF ⁇ , interferon gamma (IFNy), interleukin-1 (IL-1), interleukin-1 beta (IL-1 ⁇ ), interleukin-1 (IL-2) interleukin-6 (IL-6), interleukin-4 (IL-4), interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-13 (IL-13), interleukin-17 (IL-17), interleukin-18 (IL-18), interleukin-23 (IL-23), and lymphotoxin-a.
  • IFNy interferon gamma
  • IL-1 interleukin-1
  • IL-1 beta interleukin-1 beta
  • IL-6 interleukin-1
  • IL-4 inter
  • the cytokine is present at a concentration sufficient to induce the production or secretion of one or more proteins regulated by that cytokine.
  • the cytokine-regulated protein comprises proteins (e.g., chemokines) that are regulated by interferon gamma, including ⁇ -interferon-inducible protein 10 (IP-10), interferon-inducible T cell ⁇ -chemoattractant (I-TAC), and monokine induced by ⁇ -interferon (MIG).
  • proteins e.g., chemokines
  • IP-10 ⁇ -interferon-inducible protein 10
  • I-TAC interferon-inducible T cell ⁇ -chemoattractant
  • MIG monokine induced by ⁇ -interferon
  • IP-10, MIG, and I-TAC are expressed within CNS lesions in both Experimental Autoimmune Encephalitis (EAE) and multiple-sclerosis (MS), and the receptor that binds these ligands, CXCR3, is expressed on T cells infiltrating EAE and MS lesions as well as on T cells in the cerebrospinal fluid and periphery of MS patients during exacerbations (reviewed in Klein et al. (2004) J Immunol 172:550-559 ).
  • myleoid cell types find use in the methods of the present invention so long as they are capable of producing one or more proteins regulated by the cytokines described herein.
  • cells involved in inflammatory responses e.g., blood mononuclear cells (e.g., T cells, natural killer cells, monocytes, macrophages, etc.), blood polymorphonuclear cells (e.g., eosinophils, basophils, neutrophils, megakaryocytes, etc.), and dendritic cells.
  • Tumorigenic cell lines such as THP-1, U937, SiHa, and HL-60 are also included.
  • mammalian peripheral blood mononuclear cells as well as bone-marrow derived monocytes and monocytes isolated by elutriation or negative magnetic bead isolation may also be used.
  • the cells in the assay are cultured in serum-free media.
  • Methods for preparing serum-free media are well known in the art.
  • the ingredients may include amino-acids (both D and/or L-amino acids) such as glutamine, alanine, arginine, asparagine, cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine and their derivatives; acid soluble subgroups such as thiamine, ascorbic acid, ferric compounds, ferrous compounds, purines, glutathione and monobasic sodium phosphates.
  • amino-acids both D and/or L-amino acids
  • Additional ingredients may include sugars, deoxyribose, ribose, nucleosides, water soluble vitamins, riboflavin, salts, trace metals, lipids, acetate salts, phosphate salts, HEPES, phenol red, pyruvate salts and buffers.
  • ingredients often used in media formulations include fat soluble vitamins (including vitamins A, D, E and K), steroids and their derivatives, cholesterol, fatty acids and lipids, Tween 80, 2-mercaptoethanol pyramidines, as well as a variety of supplements including serum (fetal, horse, calf, etc.), proteins (insulin, transferrin, growth factors, hormones, etc.), antibiotics (gentamicin, penicillin, streptomycin, amphotericin B, etc.), whole egg ultra filtrate, and attachment factors (fibronectins, vitronectins, collagens, laminins, tenascins, etc.). It is well within the skilled artisan to determine the appropriate conditions under which to propagate a cell useful in the methods of the present invention.
  • the cells may be cultured in any manner known in the art including in suspension, in monolayer, on beads or in three-dimensions. Methods of cell and tissue culturing are well known in the art, and are described, for example, in Cell & Tissue Culture: Laboratory Procedures; Freshney (1987 ), Culture of Animal Cells: A Manual of Basic Techniques.
  • Induction of a cytokine-regulated protein as described herein can be evaluated in a variety of different ways, each of which is known to those of skill in the art.
  • the measurement may be either quantitative or qualitative, so long as the measurement is capable of indicating whether the level of the cytokine-regulated protein of interest in the sample is at, above, or below a reference value.
  • the level of induction, as well as the specific proteins that are induced, of one or more of the cytokine-regulated proteins can be compared to a reference cytokine induction profile (e.g., a profile that has been predetermined to correspond to a particular activity or level of activity) or to the cytokine induction profile of one or more of a reference agent and a negative control agent.
  • a negative control agent can be, e.g., one that has no potency or activity, or one that does not induce cytokine-regulated protein production in the cell type utilized in the assay, or both.
  • the cytokine induction profile can be used as a measure of a biological property or activity. Properties such as potency, specificity, and stability can be evaluated using the cytokine induction profile. For the purposes of the present invention, potency and biological activity are evaluated by evaluating the level of induction of one or more cytokine-regulated proteins. "Specificity" is evaluated, e.g., by identifying or distinguishing the tested preparation as being glatiramer acetate vs not glatiramer acetate based on the results. Stability can be evaluated by comparing the cytokine induction profile of the candidate agent to the reference agent over time. In some embodiments, the cytokine induction profile can be used as a measure of equivalence to a reference agent.
  • induction of the cytokine-regulated protein is detected using an immunological method.
  • Immunological methods which can be used to detect cytokine-regulated protein induction include, but are not limited to, competitive and non-competitive assay systems using immune-based techniques such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), multiplex ELISA, "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, and the like.
  • Immunoprecipitation protocols generally comprise obtaining supernatant from the assay media (optionally supplemented with protein phosphatase and/or protease inhibitors, e.g., ethylenediaminetetraacetic acid (EDTA), phenylmethanesulphonylfluoride (PMSF), aprotinin, sodium vanadate), adding a binding molecule of interest (i.e., a molecule, such as an antibody, that specifically binds to the cytokine-regulated protein of interest) to the supernatant, incubating for a period of time (e.g., 1 to 4 hours) at about 4° C., adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at about 4° C., washing the beads in buffer and resuspending the beads in sodium dodecyl sulfate (SDS)/sample buffer.
  • the ability of the binding molecule of interest to immunoprecipitate a particular antigen can be assessed by, e.g., Western blot analysis.
  • One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the binding molecule to a cytokine-regulated protein and decrease the background (e.g., pre-clearing the supernatant with sepharose beads).
  • immunoprecipitation protocols see, e.g., Ausubel et al., eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc. , New York at 10.16.1, which is hereby incorporated by reference herein in its entirety.
  • Western blot analysis generally comprises preparing protein samples from the assay supernatant, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%-20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with the binding molecule of interest (e.g., an antibody specific for the cytokine-regulated protein of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with an antibody (which recognizes the binding molecule, e.g., a secondary antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., 32 P or 125 I
  • ELISAs comprise preparing cytokine-regulated protein, coating the well of a 96-well microtiter plate with the cytokine-regulated protein of interest or an assay supernatant comprising the cytokine-regulated protein of interest, adding the binding molecule of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the cytokine-regulated protein.
  • an enzymatic substrate e.g., horseradish peroxidase or alkaline phosphatase
  • the binding molecule of interest does not have to be conjugated to a detectable compound; instead, an antibody (which recognizes the binding molecule of interest) conjugated to a detectable compound may be added to the well.
  • an antibody which recognizes the binding molecule of interest conjugated to a detectable compound may be added to the well.
  • the binding molecule instead of coating the well with the cytokine-regulated protein of interest or an assay supernatant comprising the cytokine-regulated protein of interest, the binding molecule may be coated to the well.
  • an antibody conjugated to a detectable compound may be added following the addition of the cytokine-regulated protein of interest or an assay supernatant comprising the cytokine-regulated protein of interest to the coated well.
  • ELISAs see, e.g., Ausubel et al, eds., 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1, which is hereby incorporated by reference herein in its entirety.
  • Various ELISA kits may be obtained from commercial sources such as BioSource International (Montreal, Canada), BD Biosciences (San Jose, CA), R&D Systems (Minneapolis, MN), Millipore Corp. (Bedford, MA), and Pierce (Rockville, IL).
  • Affinity-based measurements that utilize a molecule that specifically binds to the cytokine-regulated protein being measured may also be used, as well as other technologies, such as spectroscopy-based technologies (e.g., matrix-assisted laser desorption ionization-time of flight, or MALDI-TOF, spectroscopy).
  • an affinity reagent such as an antibody or aptamer
  • spectroscopy-based technologies e.g., matrix-assisted laser desorption ionization-time of flight, or MALDI-TOF, spectroscopy.
  • Affinity-based technologies include antibody-based assays (immunoassays as described above) and assays utilizing aptamers (nucleic acid molecules which specifically bind to other molecules), such as ELONA. Additionally, assays utilizing both antibodies and aptamers are also contemplated (e.g., a sandwich format assay utilizing an antibody for capture and an aptamer for detection). Generally, aptamers may be substituted for antibodies in nearly all formats of immunoassay, although aptamers allow additional assay formats (such as amplification of bound aptamers using nucleic acid amplification technology such as PCR ( U.S. Pat. No. 4,683,202 ) or isothermal amplification with composite primers ( U.S. Pat. Nos. 6,251,639 and 6,692,918 ).
  • Affinity-based assays may be in competition or direct reaction formats, utilize sandwich-type formats, and may further be heterogeneous (e.g., utilize solid supports) or homogenous (e.g., take place in a single phase) and/or utilize immunoprecipitation.
  • Most assays involve the use of labeled affinity reagent (e.g., antibody, polypeptide, or aptamer); the labels may be, for example, enzymatic, fluorescent, chemiluminescent, radioactive, or dye molecules.
  • Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA and ELONA assays.
  • the assay utilizes two phases (typically aqueous liquid and solid).
  • a cytokine-regulated protein-specific affinity reagent is bound to a solid support to facilitate separation of the cytokine-regulated protein from the bulk of the sample.
  • the solid support or surface containing the antibody is typically washed prior to detection of bound polypeptides.
  • the affinity reagent in the assay for measurement of cytokine-regulated proteins may be provided on a support (e.g., solid or semi-solid); alternatively, the polypeptides in the sample can be immobilized on a support or surface.
  • supports examples include nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates), polyvinylidine fluoride, diazotized paper, nylon membranes, activated beads, glass and Protein A beads. Both standard and competitive formats for these assays are known in the art.
  • Array-type heterogeneous assays are suitable for measuring levels of cytokine-regulated proteins when the methods of the invention are practiced utilizing multiple cytokine-regulated proteins.
  • Array-type assays used in the practice of the methods of the invention will commonly utilize a solid substrate with two or more capture reagents specific for different cytokine-regulated proteins bound to the substrate in a predetermined pattern (e.g., a grid).
  • the sample e.g., assay supernatant
  • cytokine-regulated proteins in the sample are bound by the capture reagents.
  • the bound cytokine-regulated proteins are detected using a mixture of appropriate detection reagents that specifically bind the various cytokine-regulated proteins. Binding of the detection reagent is commonly accomplished using a visual system, such as a fluorescent dye-based system. Because the capture reagents are arranged on the substrate in a predetermined pattern, array-type assays provide the advantage of detection of multiple cytokine-regulated proteins without the need for a multiplexed detection system.
  • the assay takes place in single phase (e.g., aqueous liquid phase).
  • the sample is incubated with an affinity reagent specific for the cytokine-regulated protein in solution.
  • an affinity reagent specific for the cytokine-regulated protein in solution.
  • it may be under conditions that will precipitate any affinity reagent/antibody complexes which are formed.
  • Both standard and competitive formats for these assays are known in the art.
  • cytokine-regulated protein/affinity reagent complex In a standard (direct reaction) format, the level of cytokine-regulated protein/affinity reagent complex is directly monitored. This may be accomplished by, for example, determining the amount of a labeled detection reagent that forms in bound to cytokine-regulated protein/affinity reagent complexes. In a competitive format, the amount of cytokine-regulated protein in the sample is deduced by monitoring the competitive effect on the binding of a known amount of labeled cytokine-regulated protein (or other competing ligand) in the complex. Amounts of binding or complex formation can be determined either qualitatively or quantitatively.
  • induction can be measured by evaluating patterns of expression of the genes encoding the cytokine-regulated proteins, or of reporter genes.
  • expression patterns can be evaluated by Northern analysis, PCR, RT-PCR, Taq Man analysis, ribonuclease protection assays, FRET detection, monitoring one or more molecular beacons, hybridization to an oligonucleotide array, hybridization to a cDNA array, hybridization to a polynucleotide array, hybridization to a liquid microarray, hybridization to a microelectric array, cDNA sequencing, clone hybridization, cDNA fragment fingerprinting, and the like.
  • the particular method elected will be dependent on such factors as quantity of RNA recovered, artisan preference, available reagents and equipment, detectors, and the like.
  • the mode of detection of the signal will depend on the exact detection system utilized in the assay. For example, if a radiolabeled detection reagent is utilized, the signal will be measured using a technology capable of quantitating the signal from the sample or of comparing the signal from the sample with the signal from a reference sample, such as scintillation counting, autoradiography (typically combined with scanning densitometry), and the like. If a chemiluminescent detection system is used, then the signal will typically be detected using a luminometer. Methods for detecting signal from detection systems are well known in the art and need not be further described here.
  • the sample may be divided into a number of aliquots, with separate aliquots used to measure different cytokine-regulated protein (although division of the sample into multiple aliquots to allow multiple determinations of the levels of the cytokine-regulated protein in a particular sample are also contemplated).
  • the sample (or an aliquot therefrom) may be tested to determine the levels of multiple cytokine-regulated protein in a single reaction using an assay capable of measuring the individual levels of different cytokine-regulated protein in a single assay, such as an array-type assay or assay utilizing multiplexed detection technology (e.g., an assay utilizing detection reagents labeled with different fluorescent dye markers).
  • Replicate measurements are ordinarily obtained by splitting a sample into multiple aliquots, and separately measuring the biomarker(s) in separate reactions of the same assay system. Replicate measurements are not necessary to the methods of the invention, but many embodiments of the invention will utilize replicate testing, particularly duplicate and triplicate testing.
  • the reference agent and the candidate agent will be assayed using separate aliquots of cells obtained from the same cell culture.
  • the reference agent (and/or negative control) and the candidate agent will be assayed using the same batch of cells. In this embodiment, each agent is assayed at different times, the assay media is replaced between measurements, and the cells are allowed to recover to an appropriate cell density following each measurement.
  • the methods described herein may be implemented and/or the results recorded using any device capable of implementing the methods and/or recording the results.
  • devices that may be used include but are not limited to electronic computational devices, including computers of all types.
  • the computer program that may be used to configure the computer to carry out the steps of the methods may be contained in any computer readable medium capable of containing the computer program. Examples of computer readable medium that may be used include but are not limited to diskettes, CD-ROMs, DVDs, ROM, RAM, and other memory and computer storage devices.
  • the computer program that may be used to configure the computer to carry out the steps of the methods and/or record the results may also be provided over an electronic network, for example, over the internet, an intranet, or other network.
  • the process of comparing a measured value and a reference value can be carried out in any convenient manner appropriate to the type of measured value and reference value for the cytokine-regulated protein at issue.
  • “measuring” can be performed using quantitative or qualitative measurement techniques, and the mode of comparing a measured value and a reference value can vary depending on the measurement technology employed. For example, when a qualitative colorimetric assay is used to measure cytokine-regulated protein levels, the levels may be compared by visually comparing the intensity of the colored reaction product, or by comparing data from densitometric or spectrometric measurements of the colored reaction product (e.g., comparing numerical data or graphical data, such as bar charts, derived from the measuring device).
  • measured values used in the methods of the invention will most commonly be quantitative values (e.g., quantitative measurements of concentration, such as nanograms of cytokine-regulated protein per milliliter of sample, or absolute amount).
  • measured values are qualitative.
  • the comparison can be made by inspecting the numerical data, or by inspecting representations of the data (e.g., inspecting graphical representations such as bar or line graphs).
  • a measured value is generally considered to be substantially similar to a reference value if it is about 80% to about 125% of the reference value.
  • the process of comparing may be manual (such as visual inspection by the practitioner of the method) or it may be automated.
  • an assay device such as a luminometer for measuring chemiluminescent signals
  • a separate device e.g., a digital computer
  • Automated devices for comparison may include stored reference values for the cytokine-regulated protein(s) being measured, or they may compare the measured value(s) with reference values that are derived from contemporaneously measured reference samples (e.g., glatiramer acetate samples).
  • the measured value that is compared with the reference value is a value that takes into account the replicate measurements.
  • the replicate measurements may be taken into account by using either the mean or median of the measured values as the "measured value.”
  • the methods and compositions of the present invention are useful for evaluating one or more properties of a batch of glatiramer acetate.
  • the methods comprise preparing a batch of glatiramer acetate, evaluating one or more of stability, specificity, potency, and biological activity using the assays described herein, and comparing the properties of the batch of glatiramer acetate to those of a reference compound (e.g., a standardized batch of glatiramer acetate, e.g., one that has been approved for therapeutic use) or reference value for a reference compound (e.g., a pharmaceutical specification for glatiramer acetate).
  • a reference compound e.g., a standardized batch of glatiramer acetate, e.g., one that has been approved for therapeutic use
  • reference value for a reference compound e.g., a pharmaceutical specification for glatiramer acetate
  • the batch of glatiramer acetate is said to be acceptable for pharmaceutical use if at least a predetermined level of one or more cytokine-regulated proteins is detected.
  • the "predetermined level” is that which can be detected using the reference compound or that which is specified in a pharmaceutical specification for glatiramer acetate.
  • THP-1 cells (ATCC, TIB-202) were received from the American Type Culture Collection (ATCC). The THP-1 cells were shown to be free of mycoplasma contamination using a multimedia direct culture assay combined with an indicator cell-DNA fluorochrome staining assay (cat. # M-250, Bionique Testing Laboratories, Inc., Saranac Lake, NY). Cells were grown in complete growth medium and incubated in a 37°C, 5% CO 2 incubator.
  • Assay medium was prepared fresh the day of the assay.
  • the assay medium consisted of 2 mM Glutamax I Supplement (Invitrogen, 35050-79) in X-VIVO 15 serum-free medium (Cambrex, 04-418Q). These reagents were filtered in a 0.2 micron cellulose acetate filter unit (Nalgene, 156-4020). After filtration, the bottle was covered with foil to protect the medium from light.
  • COPAXONE® glatiramer acetate; Teva Pharmaceuticals
  • 2X IFN- ⁇ assay medium sterile, siliconized microfuge tubes.
  • Final concentrations from 0 ⁇ g/ml to 400 ⁇ g/ml were tested in the assay.
  • Human IFN- ⁇ (R&D Systems, 285-IF-100) was reconstituted with sterile 0.2% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) (Chemicon, 3225-80).
  • BSA bovine serum albumin
  • PBS phosphate-buffered saline
  • THP-1 cells were seeded at 2 X 10 5 cells/ml (20 ml final volume). These cells were harvested by centrifugation at 400 x g, 5 rriin, 18°C. Cells were washed once with assay medium (without IFN- ⁇ ) and resuspended in assay medium (without IFN- ⁇ ) and counted. THP-1 cells were resuspended at 5 X 10 5 cells/ml in assay medium (with 0, 1, 10, and 100 ng/ml final concentration of IFN- y).
  • glatiramer acetate 50, 10, 2, and 0 ng/ml
  • Assay plates were incubated for 0 to 23 hours in a 37°C, 5% CO 2 incubator.
  • Conditioned medium was harvested into non-sterile, siliconized tubes. Tubes were centrifuged at 400 x g, 5 min, 4°C. The supernatants were transferred to new, siliconized tubes and flash frozen in liquid nitrogen. Frozen conditioned medium was stored at -80°C until they were submitted for Searchlight multiplex cytokine analysis (Pierce Endogen, Woburn, MA).
  • COPAXONE® in combination with IFN- ⁇ on secretion of a broad panel of cytokines, chemokines, soluble receptors, and proteases from THP-1 cells was examined.
  • Zip-10 is an IFN- ⁇ -regulated chemokine which binds to the CXCR3 receptor.
  • COPAXONE® treatment also resulted in higher levels of IFN- ⁇ observed in the culture medium at 24 hr, even though IFN- ⁇ was added exogenously at the start of the experiment.
  • COPAXONE® The effect of COPAXONE® on IFN- ⁇ production may account in part for its synergistic action on IP-10 secretion.
  • Other chemokines such as MCP-1 and MDC, which bind to the CCR2 and CCR4 receptors, respectively, also showed a robust secretory response to COPAXONE ®, although the magnitude of the induction was not as high as that observed with IP-10 (Table 1).
  • other cytokines such as IL6, showed a synergistic response to COPAXONE® and IFN- ⁇ .
  • Figure 1 illustrates the synergistic effect of COPAXONE® and IFN- ⁇ on the secretion of IP-10 and other chemokines.
  • THP-1 cells treated with IFN- ⁇ alone showed only a modest production of IP-10, I-TAC, and MIG (all CXCR3 ligands).
  • the addition of COPAXONE® in combination with IFN- ⁇ induced a striking, concentration-dependent effect on secretion of all three chemokines.
  • the levels of IP-10, I-TAC, and MIG secreted in the presence of 50 ⁇ g/ml COPAXONE® and 10 ng/ml IFN- ⁇ were 329-, 412-, and 573-fold higher, respectively, than baseline containing IFN- ⁇ alone. IFN- ⁇ levels measured at 24 hours also showed a concentration-dependent increase with COPAXONE® treatment.
  • the THP-1 cells were cultured in the presence of various concentrations of fetal bovine serum (FBS) or in X-VIVO15 serum-free medium.
  • COPAXONE® induced a robust secretion of all three chemokines, IP-10, MIG and I-TAC, as well as secretion of IFN- ⁇ in all conditions; however, cells cultured in the X-VIVO15 serum-free defined medium showed the highest fold induction over baseline. A similar response was seen with two other human myeloid cell lines, U-937 and HL-60; and with primary human dendritic cells.
  • Table 2 shows the fold-induction for IP-10, I-TAC, and MIG with COPAXONE® and IFN- ⁇ treatment over IFN- ⁇ alone at 23 hours.
  • the fold-induction over baseline is maximal at 1-10 ng/ml IFN- ⁇ .
  • THP-1 cells do not produce any significant amount of IP-10 when treated with COPAXONE® in the absence of IFN- ⁇ , and IFN- ⁇ alone (in the absence of COPAXONE®) induces only small amounts of chemokine secretion.
  • the synergistic effect of COPAXONE® and IFN- ⁇ is clearly illustrated in Table 2.
  • IP-10, I-TAC and MIG can be detected in the assay as early as 3-6 hours of treatment with COPAXONE® and the higher IFN- ⁇ concentrations; however, the dynamic range is better at 18-24 hours at which lower IFN- ⁇ concentrations can be used. Table 2.
  • Table 3 shows the concentration dependence of the assay. pg/ml values with standard deviations are shown for IFN- ⁇ (10 ng/ml) mediated induction of IP-10, I-TAC, and MIG at each concentration of glatiramer acetate (GA). Each value represents 12 samples from 6 independent THP-1 assays with duplicate points, each measured at 22-24 hours of incubation. In this case, the readout was Endogen Searchlight multiplex ELISA assay.
  • the absolute pg/ml numbers will be different depending on the detection method. For example, one may see a 5-10 fold difference between the Endogen Searchlight multiplex ELISA assay and a standard ELISA. Absolute numbers will also be different depending on the time of incubation and concentration of IFN- ⁇ .
  • the assay can be used to compare two or more copolymer preparations and/or to determine a reference value (e.g., an equivalence range) for comparison to values obtained with a test preparation.
  • Table 3 Glatiramer acetate (GA) dose dependence [GA] mg/ml IP-10 pg/ml ⁇ Std. Dev. I-TAC pg/ml ⁇ Std. Dev. MIG pg/ml ⁇ Std. Dev.
  • cytokines e.g., chemokines IP-10, MIG and I-TAC
  • the activity e.g., one or more of: potency, purity, stability across time, biological activity or equivalence to a reference standard
  • a sample having a greater enhancement within a comparative assay correlates with greater potency or stability.
  • the glatiramer acetate-mediated enhancement of secretion of IP-10, MIG, and I-TAC in the presence of IFN- ⁇ is an unexpected result.
  • These four soluble factors are typically associated with a Th1 pro-inflammatory cytokine response, and glatiramer acetate is thought to act, in part, by dampening a Th1 response and promoting a Th2 response.
  • glatiramer acetate The precise mechanism of action of glatiramer acetate is complex and still not fully understood but the present methods provide a way to measure a sample copolymer preparation for activity, potency, stability, specificity (e.g., for equivalence to COPAXONE® or equivalence to a pharmaceutical specification range) of a test or candidate copolymer preparation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)

Claims (14)

  1. Verfahren zum Auswerten einer Eigenschaft von Glatirameracetat, wobei das Verfahren Folgendes umfasst:
    (a) Bereitstellen von mindestens einer Myeloidzelle;
    (b) Inkontaktbringen der mindestens einen Myeloidzelle mit einer Menge an Glatirameracetat und IFN-γ in einer Konzentration und über einen Zeitraum, die/der ausreicht, um die Zelle dazu zu induzieren, ein oder mehrere Proteine zu exprimieren, die durch IFN-γ, ausgewählt aus der Gruppe bestehend aus γ-interferoninduzierbarem Protein 10 (IP-10), interferoninduzierbarem T-Zellen-a-Chemoattraktans (I-TAC) und durch γ-Interferon induziertem Monokin (MIG), induziert werden; und
    (c) Nachweisen des induzierten Proteins, ausgewählt aus der Gruppe bestehend aus γ-interferoninduzierbarem Protein 10 (IP-10), interferoninduzierbarem T-Zellen-a-Chemoattraktans (I-TAC) und durch γ-Interferon induziertem Monokin (MIG), um eine Eigenschaft von Glatirameracetat auszuwerten.
  2. Verfahren zum Auswerten von Glatirameracetat, wobei das Verfahren Folgendes umfasst:
    (a) Bereitstellen von mindestens einer Myeloidzelle, die fähig ist, ein Protein zu exprimieren, das durch IFN-γ, ausgewählt aus der Gruppe bestehend aus γ-interferoninduzierbarem Protein 10 (IP-10), interferoninduzierbarem T-Zellen-a-Chemoattraktans (I-TAC) und durch γ-Interferon induziertem Monokin (MIG), induziert wird;
    (b) Inkontaktbringen der mindestens einen Myeloidzelle mit einer Menge an Glatirameracetat und IFN-γ in einer Konzentration und über einen Zeitraum, die/der ausreicht, um die Zelle zu induzieren, das induzierte Protein zu exprimieren;
    (c) Messen der Expression, Sekretion, Induktion, das Vorhandensein oder die Menge des induzierten Proteins, ausgewählt aus der Gruppe bestehend aus γ-interferoninduzierbarem Protein 10 (IP-10), interferoninduzierbarem T-Zellen-α-Chemoattraktans (I-TAC) und durch γ-Interferon induziertem Monokin (MIG); und
    (d) Vergleichen der gemessenen Expression, Sekretion, Induktion, das Vorhandensein oder die Menge des induzierten Proteins mit einem Referenzwert, einem Cytokininduktionsprofil oder einer pharmazeutischen Spezifikation für ein pharmazeutisches Glatirameracetat-Handelspräparat, um eine Eigenschaft von Glatirameracetat auszuwerten.
  3. Verfahren nach Anspruch 1, weiterhin umfassend einen Schritt (d) des Vergleichens eines Werts für die Produktion, Sekretion, Induktion, das Vorhandensein oder die Menge des einen oder der mehreren durch IFN-γ induzierten Proteine mit einem Referenzwert, einem Cytokininduktionsprofil oder einer pharmazeutischen Spezifikation für ein pharmazeutisches Glatirameracetat-Handelspräparat.
  4. Verfahren nach Anspruch 1 oder Anspruch 3, wobei der Referenzwert, das Cytokininduktionsprofil oder die pharmazeutische Spezifikationseigenschaft für das pharmazeutische Glatirameracetat-Handelspräparat ein Wert ist, der einer Eigenschaft, ausgewählt aus der Gruppe bestehend aus Wirksamkeit, Spezifität, Stabilität, Aktivität und Kombinationen davon entspricht.
  5. Verfahren nach Anspruch 1 oder Anspruch 2, wobei die IFN-γ-Konzentration in Schritt (b) die Expression des einen oder mehreren durch IFN-γ induzierten Proteine auf ein Ausmaß induziert, das größer ist als die Summe von: i) der Expression des einen oder der mehreren durch IFN-γ induzierten Proteine, wenn die Zelle mit Glatirameracetat in Abwesenheit von IFN-γ in Kontakt gebracht wird, und ii) der Expression des einen oder der mehreren durch IFN-γ induzierten Proteine, wenn die Zelle mit IFN-γ in Abwesenheit von Glatirameracetat in Kontakt gebracht wird.
  6. Verfahren nach Anspruch 5, wobei die IFN-γ-Konzentration zwischen 0,01 ng/ml und 100 ng/ml, zwischen 1 ng/ml und 50 ng/ml, oder 10 ng/ml beträgt.
  7. Verfahren nach Anspruch 1 oder Anspruche 2, wobei der Zeitraum zwischen 1 Stunde und 48 Stunden, zwischen 6 Stunden und 36 Stunden oder zwischen 12 Stunden und 24 Stunden beträgt.
  8. Verfahren nach Anspruch 1 oder Anspruch 2, wobei die Glatirameracetatkonzentration zwischen 0,5 mg/ml und 100 mg/ml liegt, IFN-γ in einer Konzentration zwischen 1 ng/ml und 50 ng/ml vorliegt und der Zeitraum zwischen 12 Stunden und 24 Stunden beträgt und es sich bei den Zellen um THP-1-Zellen handelt.
  9. Verfahren zur Herstellung einer pharmazeutischen Glatirameracetatzusammensetzung, wobei das Verfahren Folgendes umfasst:
    (a) Bereitstellen einer Glatirameracetatcharge;
    (b) Auswerten einer Eigenschaft der Charge nach einem der Ansprüche 1 bis 8 und
    (c) wenn die Menge des einen oder der mehreren durch IFN-γ induzierten Proteine einem Referenzwert für Glatirameracetat entspricht, Feststellen, dass die Charge für die pharmazeutische Verwendung annehmbar ist.
  10. Verfahren nach Anspruch 9, wobei es sich bei dem Referenzwert um ein Zytokininduktionsprofil, einen Äquivalenzbereich oder eine pharmazeutische Spezifikation für Wirksamkeit, Spezifität, Stabilität und/oder biologische Wirksamkeit für ein pharmazeutisches Glatirameracetat-Handelspräparat handelt.
  11. Verfahren zum Auswerten der Aktivität, Wirksamkeit, Spezifität oder Stabilität eines Glatirameracetatpräparats, wobei das Verfahren Folgendes umfasst:
    (a) Bereitstellen einer Myeolidzelle;
    (b) Inkontaktbringen der Zelle mit
    (i) einer Menge an Glatirameracetat und
    (ii) INF-γ in einer Konzentration und über einen Zeitraum, die/der ausreicht, um die Zelle dazu zu induzieren, ein INF-γ-induziertes Protein, ausgewählt aus der Gruppe bestehend aus γ-interferoninduzierbarem Protein 10 (IP-10), interferoninduzierbarem T-Zellen-α-Chemoattraktans (I-TAC) und durch γ-Interferon induziertem Monokin (MIG), zu exprimieren; und
    (c) Vergleichen des Vorhandenseins, der Menge, Produktion, Sekretion, Induktion des IFN-γ-induzierten Proteins mit einem Referenzwert für Glatirameracetat.
  12. Verfahren nach einem der Ansprüche 1 bis 11, wobei es sich bei dem IFN-γ-induzierten Protein um IP-10 handelt.
  13. Verfahren nach einem der Ansprüche 1 bis 11, wobei es sich bei dem IFN-γ-induzierten Protein um I-TAC handelt.
  14. Verfahren nach einem der Ansprüche 1 bis 11, wobei es sich bei dem IFN-γ-induzierten Protein um MIG handelt.
EP11172109.8A 2007-06-21 2008-06-19 Copolymeranalyse Active EP2381254B2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94548807P 2007-06-21 2007-06-21
EP08780866A EP2174130A2 (de) 2007-06-21 2008-06-19 Copolymer-testverfahren

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP08780866.3 Division 2008-06-19
EP08780866A Division EP2174130A2 (de) 2007-06-21 2008-06-19 Copolymer-testverfahren

Publications (3)

Publication Number Publication Date
EP2381254A1 EP2381254A1 (de) 2011-10-26
EP2381254B1 EP2381254B1 (de) 2014-04-16
EP2381254B2 true EP2381254B2 (de) 2017-07-19

Family

ID=39712646

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11172109.8A Active EP2381254B2 (de) 2007-06-21 2008-06-19 Copolymeranalyse
EP08780866A Ceased EP2174130A2 (de) 2007-06-21 2008-06-19 Copolymer-testverfahren

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08780866A Ceased EP2174130A2 (de) 2007-06-21 2008-06-19 Copolymer-testverfahren

Country Status (9)

Country Link
US (1) US8753833B2 (de)
EP (2) EP2381254B2 (de)
JP (1) JP2010530975A (de)
CN (1) CN101743470A (de)
AU (1) AU2008265692A1 (de)
CA (1) CA2690402A1 (de)
ES (1) ES2477232T5 (de)
IL (1) IL202613A0 (de)
WO (1) WO2008157697A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120097520A (ko) * 2009-11-17 2012-09-04 아레스 트레이딩 에스.에이. 랜덤 서열 중합체 조성물의 혈청 단백질­기반 검출을 통한 랜덤 서열 중합체 조성물의 설계，생체이용률，및 효능을 개선시키는 방법
US20130210054A1 (en) * 2012-02-09 2013-08-15 Momenta Pharmaceuticals, Inc. Amino Acid Copolymer Assay
WO2013139728A1 (en) 2012-03-19 2013-09-26 Synthon Bv Glatiramer acetate human monocyte cell-based potency assay
EP2642290A1 (de) 2012-03-19 2013-09-25 Synthon BV Potenztest basierend auf der humanen Glatiramer-Acetatmonzytzelllinie
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
CN102901831B (zh) * 2012-10-25 2015-01-14 杭州宝康亿富生物科技有限公司 一种免疫调节多糖生物活性检测方法
WO2014107533A2 (en) * 2013-01-04 2014-07-10 Teva Pharmaceutical Industries Ltd. Characterizing a glatiramer acetate related drug product
US10344330B2 (en) 2013-03-14 2019-07-09 Mylan Inc. Glatiramer acetate response biomarker mRNA potency assay
WO2014173463A1 (en) 2013-04-26 2014-10-30 Synthon Bv Glatiramer acetate human monocytic cell line-based potency assay
US9995734B2 (en) 2013-10-24 2018-06-12 Mylan Inc. Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
TW201610169A (zh) * 2014-07-01 2016-03-16 泰瓦藥品工業有限公司 利用哺乳動物及人類細胞進行之格拉雷姆（ｇｌａｔｉｒａｍｅｒ）乙酸鹽相關藥物產品之生物特徵化
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
JP6522778B2 (ja) * 2015-11-10 2019-05-29 株式会社日立製作所 癌検査システム及び癌検査評価方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA2023176A1 (en) 1989-08-25 1991-02-26 Margaret M. Bowers-Daines Preparation and use of iodopropargyl esters of a-amino acid derivatives as antimicrobial agents
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6692918B2 (en) 1999-09-13 2004-02-17 Nugen Technologies, Inc. Methods and compositions for linear isothermal amplification of polynucleotide sequences
DE60009323T2 (de) 1999-09-13 2005-02-10 Nugen Technologies, Inc., San Carlos Methoden und zusammensetzungen zur linearen isothermalen amplifikation von polynukleotidsequenzen
EP1459065B1 (de) * 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Verfahren zur messung der wirkstärke von glatirameracetat
AU2003263793A1 (en) 2002-07-19 2004-02-09 Lg Life Sciences Dendrimers as molecular translocators
AU2003283152A1 (en) 2002-11-13 2004-06-03 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
CA2411786C (en) 2002-11-13 2009-01-27 Brantford Chemicals Inc. A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
EP1807467B1 (de) * 2004-10-29 2009-08-26 Sandoz AG Verfahren zur herstellung von glatiramer
EP1922345A4 (de) 2005-08-15 2009-11-11 Chan Wai Hong Verfahren zur herstellung von copolymer-1
WO2007047202A1 (en) 2005-10-11 2007-04-26 Schering Corporation Substituted heterocyclic compounds with cxcr3 antagonist activity

Also Published As

Publication number Publication date
ES2477232T5 (es) 2017-11-23
WO2008157697A3 (en) 2009-03-26
IL202613A0 (en) 2010-06-30
JP2010530975A (ja) 2010-09-16
CN101743470A (zh) 2010-06-16
EP2381254A1 (de) 2011-10-26
ES2477232T3 (es) 2014-07-16
AU2008265692A1 (en) 2008-12-24
US8753833B2 (en) 2014-06-17
US20110053203A1 (en) 2011-03-03
WO2008157697A2 (en) 2008-12-24
CA2690402A1 (en) 2008-12-24
EP2174130A2 (de) 2010-04-14
EP2381254B1 (de) 2014-04-16

Similar Documents

Publication Publication Date Title
EP2381254B2 (de) Copolymeranalyse
Okada et al. Human STAT1 gain-of-function heterozygous mutations: chronic mucocutaneous candidiasis and type I interferonopathy
Lammers et al. Identification of a novel immunomodulatory gliadin peptide that causes interleukin‐8 release in a chemokine receptor CXCR3‐dependent manner only in patients with coeliac disease
Cannon et al. Measuring circulating cytokines
Lebovic et al. IL-1β induction of RANTES (regulated upon activation, normal T cell expressed and secreted) chemokine gene expression in endometriotic stromal cells depends on a nuclear factor-κB site in the proximal promoter
Kurzrock et al. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms
Chen et al. Tumour necrosis factor‐α stimulates human neutrophils to release preformed activin A
WO2004053452A2 (en) Assays relating to toll-like receptor activity
JP2005500510A (ja) インターフェロンαを選択的に誘導する化合物を同定するための選別法
Martinez et al. Nonspecific suppressor cell function in atopic subjects
AU2008273814A1 (en) IL-23 receptor antagonists and uses thereof
JP2014513289A (ja) ＩＦＮβに対する治療応答性を予測するバイオマーカーおよびその使用
Monteleone et al. Immunoendocrine findings in patients with eating disorders
KR20020021774A (ko) 전염성 해면체성 뇌병증 진단 방법
EP0710839B1 (de) Verfahren zum Nachweis von Interferonaktivität
Crepaldi et al. Molecular basis of the synergistic production of IL‐1 receptor antagonist by human neutrophils stimulated with IL‐4 and IL‐10
KR101753850B1 (ko) 아토피 피부염 또는 면역력 감소 여부를 진단하는 dock8 단백질
WO2013139728A1 (en) Glatiramer acetate human monocyte cell-based potency assay
Saresella et al. TH17-driven inflammation is present in all clinical forms of multiple sclerosis; disease quiescence is associated with GATA3-expressing cells
US20220381769A1 (en) Immune Assay for Monitoring Response to Oncolytic Vaccinia Virus and Uses Thereof
EP1369695B1 (de) Verfahren zur Identifizierung von auf Ifn-Beta ansprechenden multiple Sklerose Patienten, durch die Bestimmung der Expression von Trail
Du et al. Mercuric chloride stimulates distinct signal transduction pathway for DNA synthesis in a T‐cell line, CTLL‐2
Cook et al. Upregulation of dynamin II expression during the acquisition of a mature pancreatic acinar cell phenotype.
US20090215044A1 (en) Receptor in Dendritic Cells
Adithya et al. TNFα increases tyrosine hydroxylase expression in human monocytes

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 20110630

AC Divisional application: reference to earlier application

Ref document number: 2174130

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17Q First examination report despatched

Effective date: 20111104

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20131120

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KISHIMOTO, TAKASHI KEI

Inventor name: HEALY, AILEEN

Inventor name: D'ALESSANDRO, JOSEPHINE S.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 2174130

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 662859

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008031627

Country of ref document: DE

Effective date: 20140528

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2477232

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140716

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 662859

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140416

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140816

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140717

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140716

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140716

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140818

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602008031627

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140619

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26 Opposition filed

Opponent name: SYNTHON B.V.

Effective date: 20150115

Opponent name: ACTAVIS GROUP PTC EHF

Effective date: 20150115

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602008031627

Country of ref document: DE

Effective date: 20150115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140619

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140630

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20080619

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

27A Patent maintained in amended form

Effective date: 20170719

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602008031627

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2477232

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20171123

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230711

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240515

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240502

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240502

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240509

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240704

Year of fee payment: 17